# Galleri Multi-Cancer Early Detection

**Category:** diagnostic
**Evidence Grade:** B
**Risk Profile:** low

## Description
Blood test by GRAIL that screens for 50+ cancer types via cell-free DNA methylation patterns. Detects cancer signal and predicts tissue of origin. Designed as complement to standard screening, especially for cancers without current screening methods.

## Mechanisms of Action
- Cell-free DNA (cfDNA) methylation analysis
- Cancer signal detection across 50+ types
- Tissue of origin prediction

## Dosage
- **Standard:** Blood draw, annually
- **Range:** Annually
- **Notes:** Recommended for adults 50+ or high-risk individuals. Complement to (not replacement for) standard screenings. ~0.5% false positive rate.

## Key Findings
- Detected 50+ cancer types with 51.5% sensitivity in PATHFINDER study
- Predicted tissue of origin with 88% accuracy
- NHS-Galleri trial (140,000 participants) â€” largest cancer screening trial ever

## Interactions


## Side Effects
- Venipuncture
- Psychological impact of results

## Contraindications
- Already undergoing cancer treatment (may confound results)

## Sources


## Suppliers


---
*Last updated: 2026-02-04T14:50:14.798Z*
